{"name":"Huib A.M. Kerstjens","slug":"huib-a-m-kerstjens","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Morphine Retard","genericName":"Morphine Retard","slug":"morphine-retard","indication":"Moderate to severe chronic pain","status":"marketed"}]}],"pipeline":[{"name":"Morphine Retard","genericName":"Morphine Retard","slug":"morphine-retard","phase":"marketed","mechanism":"Morphine Retard is a sustained-release formulation of morphine that binds to opioid receptors in the central nervous system to provide prolonged pain relief.","indications":["Moderate to severe chronic pain","Cancer pain"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNREVwblhUZG1YajdxSjVrQzZWWVJJMk5GSUxGWDFScU9UTkFLZjJSNUYtTi1pejIxY2NueHBJc3RVNXhHRGxBTzRsNDI2VGxIdW9PeW1kVmwtUFctRDVOSHZCODRSWVBkb2tpRUVnOUN0STNGSzZ1cjFiNGdyY1B3VkhaeDlzakVaZjBOdw?oc=5","date":"2024-06-28","type":"pipeline","source":"Frontiers","summary":"Pharmacological Rationale for Targeting IL-17 in Asthma - Frontiers","headline":"Pharmacological Rationale for Targeting IL-17 in Asthma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQRGg1d25ESmh5dHJwQmJ5Y1lHaG5jZXpzWDRBZWlkV3BHYzVPWEhDNElvajV5SnBHbTAzcjdfS0xYTF9sZk1HM01Hd21zY2t1TUk1TWs0bXhUWS1rY0pSWGZ1N2lYSFZwRWNFcmQxUDRlWnFMeF9ZUml4YmhvU3I5WG5SYm9RaW55ZjE4?oc=5","date":"2020-09-07","type":"trial","source":"The Lancet","summary":"Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma (IRIDIUM): a random","headline":"Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticason","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE9lYjNKYWNHUnFvZW52YXQxckdycUlrYk5qWDFjeXVlSzBRZ05mM2NHaUNObVlJMjNsREFrT0VsUVAxQkNsZlZ6VXBTSXlwdDdfZGx2ZUh4RzBCTHpoeU5FeQ?oc=5","date":"2017-09-12","type":"pipeline","source":"NEJM","summary":"Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease - NEJM","headline":"Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE53RUkxVmRPeXpXNWduSlVmWFk5SHV0eGhraFBNVWd0RHJsdHY5aElPc09scUl1WVNuckhqckhSb0xZNmk0RDY5b3BkMEZfN29ueEM1bW1rbUU?oc=5","date":"2014-07-10","type":"pipeline","source":"nature.com","summary":"Development of the Assessment of Burden of COPD tool: an integrated tool to measure the burden of COPD - nature.com","headline":"Development of the Assessment of Burden of COPD tool: an integrated tool to measure the burden of COPD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE92TVRjd3BoTG94dE1RM29ZQ3RCSkhHMWZLZEdvcU5NT0wyOUV1cXZNanN6bEgwNElMM1pjZlZtNTVwUUpFLVpsQnVtRVZIUk5TOGNFWnJIWDB0eGpnLVloVw?oc=5","date":"2012-09-03","type":"pipeline","source":"NEJM","summary":"Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy - NEJM","headline":"Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE1SdmJoS1hOdVAtVU40dGU4OFNZSmxSRW5RMU1TaFZWYVhKbjRYZnd2RTVtenFxLW1BajM4YzVBSWMwWjdKS09DR1NyLUZQdEppSzBvbXVTS3dyRllrWnZIdi1xUVIwWnM?oc=5","date":"1992-11-12","type":"pipeline","source":"NEJM","summary":"A Comparison of Bronchodilator Therapy with or without Inhaled Corticosteroid Therapy for Obstructive Airways Disease - NEJM","headline":"A Comparison of Bronchodilator Therapy with or without Inhaled Corticosteroid Therapy for Obstructive Airways Disease","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}